GILD - Gilead Sciences, Inc.
82.75 +2.74 (3.42%)
After hours: 7:59PM EDT
| Previous Close | 80.24 |
| Open | 80.26 |
| Bid | 82.60 x 200 |
| Ask | 82.95 x 1500 |
| Day's Range | 79.76 - 80.84 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 7,181,878 |
| Avg. Volume | 9,317,576 |
| Market Cap | 104.49B |
| Beta | 0.90 |
| PE Ratio (TTM) | 8.69 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.08 (2.56%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- CNBC Videos•6 hours ago
Gilead's newly approved cancer drug priced at $373,000
CNBC's Meg Tirrell reports on the FDA approving Gilead's cancer drug and what its priced at.
- Investor's Business Daily•15 minutes ago
These Are 5 Notable Stocks Moving Overnight, Including This Top Biotech: S&P 500 Futures
Adobe Systems skyrocketed overnight on earnings guidance while eBay fell on its outlook. Gilead Sciences rallied on its big FDA win, also lifting Juno Therapeutics.
- The Wall Street Journal•28 minutes ago
Gilead Gets FDA Approval for New Cancer Therapy
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
- Reuters•4 hours ago
U.S. FDA approves Gilead cancer gene therapy; price set at $373,000
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.
- Reuters•5 hours ago
Gilead cancer immunotherapy wins U.S. approval with $373,000 price
A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fighting cancer. Gilead said the price for the therapy with one-time administration would be $373,000. Gilead Sciences shares rose almost 4 percent to $83 in extended trading.
- Reuters•6 hours ago
FDA approves Gilead's Yescarta cancer immunotherapy
A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of ...
- Zacks•9 hours ago
Top Stock Reports for IBM, Celgene and Procter & Gamble
Top Stock Reports for IBM, Celgene and Procter & Gamble
- Market Realist•13 hours ago
Inside Gilead’s HBV Portfolio Performance in 1H17
In 1H17, Gilead Sciences' (GILD) Viread generated revenues of ~$560 million, compared with $559 in 1H16.
- Market Realist•15 hours ago
How Gilead’s HCV Drug Portfolio Is Positioned after 1H17
In 1H17, Gilead Sciences’ (GILD) Harvoni reported revenues of ~$2.75 billion, compared with $5.58 billion in 1H16.
Markit•16 hours agoSee what the IHS Markit Score report has to say about Gilead Sciences Inc.
Gilead Sciences Inc NASDAQ/NGS:GILD
- Zacks•yesterday
Where to Find Value in Healthcare Stocks
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
- Motley Fool•yesterday
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Both of these small-cap biotechs are advancing new cancer therapies, but which stock is the best pick right now?
- Market Realist•yesterday
US Pharma Mergers and Acquisitions in 3Q17
Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
- Zacks•yesterday
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
- Market Realist•2 days ago
This Could Really Drive Gilead’s Revenue Growth in 2018
FDA approval of BIC/FTC/TAF is expected to strengthen Gilead Sciences’ HIV franchise.
- Zacks•2 days ago
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
- Market Realist•2 days ago
How Gilead Sciences Is Positioned after 1H17
In 1H17, Gilead Sciences (GILD) reported revenues of ~$13.4 billion, compared with to $15.6 billion in 1H16.
- Market Realist•2 days ago
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
- Barrons.com•2 days ago
[$$] More Biotechs That Can Beat Q3 Views
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
- Forbes•2 days ago
Berkshire Hathaway And 6 Other Piggyback Stocks To Profit From
Seven buy list stocks from some of the greatest value investors.
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
- Investor's Business Daily•3 days ago
6 Top Biotech Companies In Innovation Earn Recognition In New Awards
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
- Investor's Business Daily•3 days ago
Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
- The Wall Street Journal•3 days ago
[$$] Nimbus Therapeutics Strikes Immunology Deal With Celgene
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
- Zacks•5 days ago
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
